GLP-1 receptor agonists (GLP-1RAs) are medications commonly used to treat type 2 diabetes, obesity, and metabolic liver diseases. A meta-analysis of 55 randomized trials involving over 106,000 participants examined their gastrointestinal safety.
GLP-1 receptor agonists (GLP-1RAs) are medications commonly used to treat type 2 diabetes, obesity, and metabolic liver diseases. A meta-analysis of 55 randomized trials involving over 106,000 participants examined their gastrointestinal safety. The study found that GLP-1RAs are linked to a 46% higher risk of cholelithiasis (gallstones), which equals about 2 extra cases per 1000 people treated. Additionally, they were associated with a twofold increased risk of gastroesophageal reflux disease (GERD), leading to 4 extra cases per 1000 patients. However, no significant increase was observed in other gastrointestinal risks like pancreatitis, cholangitis, or intestinal obstruction.
The risks of gallstones and GERD were more pronounced in patients with obesity, liver conditions like MASLD/MASH, those using GLP-1RAs for weight loss, or taking higher doses. These effects may result from rapid weight loss and reduced gallbladder motility (for gallstones) or delayed gastric emptying (for GERD). Despite these risks, GLP-1RAs are considered safe overall, as severe gastrointestinal complications were not significantly elevated.
Clinicians should monitor gallbladder and reflux symptoms in patients on GLP-1RAs, especially those on weight-loss formulations or higher doses. The benefits of these drugs often outweigh their modest risks, making them a valuable therapeutic option.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.